Showing results (201-210 of 620) with videos related to
Sort By:
Pageof 62
Rheumatology Advances in Practice|June 6, 2022
Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT studyGyörgy Nagy, Pál Géher, László Tamási, et al.Rheumatology Advances in Practice|July 8, 2022
Perceptions of risk in people with inflammatory arthritis during the COVID-19 pandemicSarah Ryan, Paul Campbell, Zoe Paskins, et al.Rheumatology Advances in Practice|July 5, 2022
Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patientsEbru Dirikgil, Sander W Tas, Cornelis A Verburgh, et al.Rheumatology Advances in Practice|June 7, 2021
Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR)Chengappa Kavadichanda, Vineeta Shobha, Parasar Ghosh, et al.Rheumatology Advances in Practice|November 20, 2020
Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?Aleksandra Antovic, Einar Svensson, Björn Lövström, et al.Rheumatology Advances in Practice|February 22, 2020
The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologistDiederik De Cock, Kristien Van der Elst, Veerle Stouten, et al.Rheumatology Advances in Practice|April 26, 2021
Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case seriesMichael Dick, Julia Martin, Nicola TugnetRheumatology Advances in Practice|April 7, 2023
Cocaine-induced granulomatosis with polyangiitis-an under-recognized conditionCharn Gill, Joseph Sturman, Leyla Ozbek, et al.Rheumatology Advances in Practice|May 1, 2023
Correction to: How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy IndexRheumatology Advances in Practice|May 1, 2023
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE studyBruno Fautrel, Yoram Bouhnik, Philippe Dieude, et al.Pageof 62